GSK2556286 (GSK286) is an orally active inhibitor of M. tuberculosis. GSK2556286 inhibits growth within human macrophages (IC 50 = 0.07?μM). GSK2556286 is effective against both multidrug-resistant (MDR) or extensively drug-resistant (XDR) and drug-sensitive (DS) M. tuberculosis.
性状
Solid
IC50 & Target[1][2]
IC50: 0.07?μM (human macrophage)
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Nuermberger EL, et al. GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment. Antimicrob Agents Chemother. 2022 May 24:e0013222.
溶解度数据
In Vitro: DMSO : 3.33 mg/mL (10.11 mM; ultrasonic and warming and heat to 60°C)配制储备液
[1]. Nuermberger EL, et al. GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment. Antimicrob Agents Chemother. 2022 May 24:e0013222.